Dovitinib regulatory strategy confirmed and new combination biomarker DRP PD1/PD-L1 + dovitinib developed. Oncology Venture engages in partnering activities with Destum Partners

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment